上海凯宝(300039)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300039 上海凯宝

已收盘 02-04 15:00:00

{"stockData":{"symbol":"300039","market":"SZ","secType":"STK","nameCN":"上海凯宝","latestPrice":6.24,"timestamp":1770188631000,"preClose":6.21,"halted":0,"volume":11935009,"delay":0,"changeRate":0.0048,"floatShares":917000000,"shares":1046000000,"eps":0.3304,"marketStatus":"已收盘","change":0.03,"latestTime":"02-04 15:00:00","open":6.18,"high":6.25,"low":6.18,"amount":74171200,"amplitude":0.0113,"askPrice":6.24,"askSize":1445,"bidPrice":6.23,"bidSize":2551,"shortable":0,"etf":0,"ttmEps":0.3304,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770255000000},"marketStatusCode":5,"adr":0,"adjPreClose":6.21,"symbolType":"stock","openAndCloseTimeList":[[1770168600000,1770175800000],[1770181200000,1770188400000]],"highLimit":6.83,"lowLimit":5.59,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1046000000,"isCdr":false,"pbRate":1.43,"roa":"--","peRate":18.886199,"roe":"10.79%","epsLYR":0.3591,"committee":-0.050677,"marketValue":6527000000,"turnoverRate":0.013,"status":0,"floatMarketCap":5722000000},"requestUrl":"/m/hq/s/300039/tweets","defaultTab":"tweets","newsList":[{"id":"2609239173","title":"股市必读：上海凯宝（300039）2月4日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2609239173","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609239173?lang=zh_cn&edition=full","pubTime":"2026-02-05 01:38","pubTimestamp":1770226691,"startTime":"0","endTime":"0","summary":"截至2026年2月4日收盘，上海凯宝报收于6.24元，上涨0.48%，换手率1.3%，成交量11.94万手，成交额7417.12万元。董秘最新回复投资者： 公司有那么多现金拿去买理财产品，为什么不拿点钱回购公司股票注销呢！公司核心产品痰热清系列产品是否有所影响，公司有所应对措施。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500000967.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0188","300039"],"gpt_icon":0},{"id":"2608358992","title":"上海凯宝：公司生产经营正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2608358992","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608358992?lang=zh_cn&edition=full","pubTime":"2026-02-04 15:13","pubTimestamp":1770189194,"startTime":"0","endTime":"0","summary":"证券之星消息，上海凯宝(300039)02月04日在投资者关系平台上答复投资者关心的问题。投资者提问：请问，上海凯空，为何天天跌，年年跌，是经营出现问题了吗？谢谢回答上海凯宝回复：投资者您好，公司生产经营正常。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400019995.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300039","BK0028","BK0188","BK0239"],"gpt_icon":0},{"id":"2590314488","title":"上海凯宝（300039）披露公司及子公司产品在国家医保目录（2025年）中调整情况，12月09日股价下跌1.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590314488","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590314488?lang=zh_cn&edition=full","pubTime":"2025-12-09 17:47","pubTimestamp":1765273649,"startTime":"0","endTime":"0","summary":"截至2025年12月9日收盘，上海凯宝报收于6.3元，较前一交易日下跌1.41%，最新总市值为65.9亿元。近日，上海凯宝发布关于公司及子公司产品在国家医保目录中调整情况的公告。公告显示，2025年12月7日，国家医保局等部门公布《国家基本医疗保险、工伤保险和生育保险药品目录》。上海凯宝及子公司共有92个药品纳入目录，其中甲类50个，乙类42个。痰热清胶囊医保支付标准为4.09元/粒，协议有效期至2027年12月31日。上述调整自2026年1月1日起执行。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900027767.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300039","BK0188","BK0028","BK0239"],"gpt_icon":0},{"id":"2584308611","title":"上海凯宝（300039）披露2025年前三季度权益分派实施公告，11月20日股价上涨0.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584308611","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584308611?lang=zh_cn&edition=full","pubTime":"2025-11-20 22:16","pubTimestamp":1763648184,"startTime":"0","endTime":"0","summary":"截至2025年11月20日收盘，上海凯宝报收于6.36元，较前一交易日上涨0.47%，最新总市值为66.53亿元。该股当日开盘6.34元，最高6.41元，最低6.3元，成交额达1.24亿元，换手率为2.13%。公司近日发布公告称，2025年前三季度利润分配方案为：以公司总股本1,046,000,000股为基数，向全体股东每10股派0.30元人民币现金（含税）。本次权益分派股权登记日为2025年11月26日，除权除息日为2025年11月27日。分配方案经2025年第一次临时股东大会审议通过，且实施期间公司总股本未发生变化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000038131.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300039","BK0239","BK0188","BK0028"],"gpt_icon":0},{"id":"2584955353","title":"上海凯宝（300039）披露更换持续督导保荐代表人公告，11月18日股价下跌1.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584955353","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584955353?lang=zh_cn&edition=full","pubTime":"2025-11-18 22:15","pubTimestamp":1763475317,"startTime":"0","endTime":"0","summary":"截至2025年11月18日收盘，上海凯宝报收于6.44元，较前一交易日下跌1.08%，最新总市值为67.36亿元。公司于近日发布公告称，上海凯宝药业股份有限公司收到东吴证券通知，原持续督导保荐代表人刘婷女士因工作变动不再履行相关职责，东吴证券已委派翟悦女士接替其持续督导工作。变更后，公司持续督导保荐代表人为翟悦女士和曹飞先生，持续督导期截止至公司首次公开发行股票募集资金使用完毕。公司董事会对刘婷女士在任期间的贡献表示感谢。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800039781.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300039","BK0028","BK0188"],"gpt_icon":0},{"id":"2582210423","title":"上海凯宝（300039）披露获得《药物临床试验批准通知书》，11月12日股价下跌0.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582210423","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582210423?lang=zh_cn&edition=full","pubTime":"2025-11-12 17:35","pubTimestamp":1762940126,"startTime":"0","endTime":"0","summary":"截至2025年11月12日收盘，上海凯宝报收于6.5元，较前一交易日下跌0.15%，最新总市值为67.99亿元。该股当日开盘6.53元，最高6.58元，最低6.46元，成交额达2.2亿元，换手率为3.68%。公司近日发布公告称，上海凯宝药业股份有限公司于近日获得国家药品监督管理局签发的《药物临床试验批准通知书》，同意公司申报的中药1.1类新药KBZ24020开展用于急性缺血性脑卒中的临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200028728.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0239","300039"],"gpt_icon":0},{"id":"2581178777","title":"股市必读：上海凯宝（300039）11月5日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2581178777","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581178777?lang=zh_cn&edition=full","pubTime":"2025-11-06 00:59","pubTimestamp":1762361952,"startTime":"0","endTime":"0","summary":"截至2025年11月5日收盘，上海凯宝报收于6.33元，上涨2.1%，换手率3.69%，成交量33.87万手，成交额2.13亿元。董秘最新回复投资者： 董秘您好，我想知晓一下最新截止到10月10号的股东人数，谢谢董秘： 投资者您好，股东人数请致电021-37572069。当日关注点来自交易信息汇总：11月5日主力资金净流入2305.85万元，呈现明显吸筹迹象。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600000913.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300039","BK0188","BK0028","BK0239"],"gpt_icon":0},{"id":"2579602978","title":"上海凯宝(300039)9月30日股东户数4.93万户，较上期减少6.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579602978","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579602978?lang=zh_cn&edition=full","pubTime":"2025-10-29 17:32","pubTimestamp":1761730365,"startTime":"0","endTime":"0","summary":"证券之星消息，近日上海凯宝披露，截至2025年9月30日公司股东户数为4.93万户，较6月30日减少3172.0户，减幅为6.04%。在中药行业个股中，上海凯宝股东户数低于行业平均水平，截至9月30日，中药行业平均股东户数为5.34万户。从股价来看，2025年6月30日至2025年9月30日，上海凯宝区间涨幅为0.17%，在此期间股东户数减少3172.0户，减幅为6.04%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900036321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300039","BK0188","BK0028","BK0239"],"gpt_icon":0},{"id":"2579957189","title":"图解上海凯宝三季报：第三季度单季净利润同比下降13.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579957189","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579957189?lang=zh_cn&edition=full","pubTime":"2025-10-29 03:17","pubTimestamp":1761679057,"startTime":"0","endTime":"0","summary":"证券之星消息，上海凯宝2025年三季报显示，公司主营收入8.19亿元，同比下降26.95%；归母净利润1.87亿元，同比下降13.83%；扣非净利润1.73亿元，同比下降18.47%；其中2025年第三季度，公司单季度主营收入2.14亿元，同比下降26.61%；单季度归母净利润6508.77万元，同比下降13.13%；单季度扣非净利润5533.54万元，同比下降19.83%；负债率8.32%，投资收益1491.2万元，财务费用-2611.06万元，毛利率80.74%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900003418.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300039"],"gpt_icon":0},{"id":"2563906522","title":"股市必读：上海凯宝中报 - 第二季度单季净利润同比下降29.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563906522","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563906522?lang=zh_cn&edition=full","pubTime":"2025-08-29 03:39","pubTimestamp":1756409991,"startTime":"0","endTime":"0","summary":"截至2025年8月28日收盘，上海凯宝报收于6.32元，下跌3.07%，换手率7.46%，成交量68.42万手，成交额4.33亿元。业绩披露要点财务报告上海凯宝2025年中报显示，公司主营收入6.05亿元，同比下降27.08%；归母净利润1.22亿元，同比下降14.2%；扣非净利润1.17亿元，同比下降17.81%。2025年第二季度单季度主营收入2.04亿元，同比下降42.31%；单季度归母净利润3766.13万元，同比下降29.84%；单季度扣非净利润3556.07万元，同比下降35.9%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082900004152.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300039"],"gpt_icon":0},{"id":"2562269746","title":"上海凯宝(300039.SZ)发布上半年业绩，归母净利润1.22亿元，下降14.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562269746","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562269746?lang=zh_cn&edition=full","pubTime":"2025-08-27 20:24","pubTimestamp":1756297454,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海凯宝(300039.SZ)发布2025年半年度报告，该公司营业收入为6.05亿元，同比减少27.08%。归属于上市公司股东的净利润为1.22亿元，同比减少14.20%。归属于上市公司股东的扣除非经常性损益的净利润为1.17亿元，同比减少17.81%。基本每股收益为0.1166元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1336519.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300039"],"gpt_icon":0},{"id":"2561410055","title":"上海凯宝：痰热清注射液主要围绕二级及以上医院市场发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2561410055","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561410055?lang=zh_cn&edition=full","pubTime":"2025-08-22 08:36","pubTimestamp":1755822974,"startTime":"0","endTime":"0","summary":"证券之星消息，上海凯宝(300039)08月21日在投资者关系平台上答复投资者关心的问题。投资者提问：请问：痰热清注射液以及痰热清胶囊是否已经列入国家医保目录？是处方药吗？在何级医院可以配到？零售药房有购吗？谢谢！上海凯宝回复：投资者您好，公司产品痰热清注射液、痰热清胶囊均为处方药，痰热清注射液主要围绕二级及以上医院市场发展，痰热清胶囊和可在有关医院、药店及网络药店购买。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082200007800.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0239","300039"],"gpt_icon":0},{"id":"2518244697","title":"上海凯宝(300039.SZ)全资子公司获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2518244697","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518244697?lang=zh_cn&edition=full","pubTime":"2025-03-10 19:04","pubTimestamp":1741604677,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海凯宝(300039.SZ)公告，公司全资子公司上海凯宝新谊(新乡)药业有限公司(简称“子公司”)，近日收到国家药品监督管理局签发的多索茶碱片《药品注册证书》。多索茶碱片适用于支气管哮喘、喘息性慢性支气管炎及其他支气管痉挛引起的呼吸困难。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259927.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300039","BK0188","BK0028","BK0239"],"gpt_icon":0},{"id":"2512315365","title":"上海凯宝：公司生产经营正常，不存在应披露未披露事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2512315365","media":"证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512315365?lang=zh_cn&edition=full","pubTime":"2025-02-18 18:37","pubTimestamp":1739875020,"startTime":"0","endTime":"0","summary":"证券日报网讯上海凯宝2月18日在互动平台回答投资者提问时表示，公司始终将产品质量与安全作为企业发展的第一要务，坚持“质量、创新、品牌”三核驱动现代中药高质量发展管理模式。截至目前，公司生产经营正常，不存在应披露未披露事项。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-02-18/doc-inekxfhx6959159.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK0188","BK0028","300039"],"gpt_icon":0},{"id":"2512182341","title":"上海凯宝：截至目前优欣定项目处于III期临床研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2512182341","media":"互动易","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512182341?lang=zh_cn&edition=full","pubTime":"2025-02-18 12:09","pubTimestamp":1739851740,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 有投资者向上海凯宝提问， 请问贵公司的优欣定开发的最近进度到哪里了？？公司回答表示，投资者您好，截至目前优欣定项目处于III期临床研究阶段。后续达到披露节点将及时予以公告。感谢您的关注！\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-02-18/doc-inekwqmn6824696.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0188","BK4134","BK0028","BK0239","III","300039"],"gpt_icon":0},{"id":"2511679135","title":"【上海凯宝在海南投资新设医疗科技公司】 公开资料显示，近日，海南凯交醇医疗科技有限公司成立，法定代表人为张小利，注册资本100万元，经营范围包含：第二类医疗器械生产；第三类医疗器械生产；第三类医疗器械经营等。股权数据显示，该公司由上海凯宝旗下上海凯合交医疗科技有限公司全资持股。","url":"https://stock-news.laohu8.com/highlight/detail?id=2511679135","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511679135?lang=zh_cn&edition=full","pubTime":"2025-02-13 13:55","pubTimestamp":1739426144,"startTime":"0","endTime":"0","summary":"公开资料显示，近日，海南凯交醇医疗科技有限公司成立，法定代表人为张小利，注册资本100万元，经营范围包含：第二类医疗器械生产；第三类医疗器械生产；第三类医疗器械经营等。股权数据显示，该公司由上海凯宝旗下上海凯合交医疗科技有限公司全资持股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/13135548133064.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["300039","BK1100","09997","BK1574","BK1222","BK0188","BK0239","BK1583","159883","159891","09996","BK0028"],"gpt_icon":0},{"id":"2509011794","title":"上海凯宝最新公告：获得苓桂术甘汤颗粒《药品注册证书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2509011794","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509011794?lang=zh_cn&edition=full","pubTime":"2025-02-07 17:04","pubTimestamp":1738919057,"startTime":"0","endTime":"0","summary":"上海凯宝药业股份有限公司近日收到国家药品监督管理局签发的苓桂术甘汤颗粒《药品注册证书》。该药品为中药3.1类，功能主治为温阳化饮，健脾利湿，用于中阳不足之痰饮。此次获得药品注册证书，将进一步丰富公司产品线，提升市场竞争力，促进古代经典名方新药转化及其在现代临床中的广泛应用。但该产品的生产和销售受国家政策、市场环境等因素影响，具有不确定性。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025020700026351.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300039","BK0188","BK0028","BK0239"],"gpt_icon":0},{"id":"2509996117","title":"上海凯宝(300039.SZ)：苓桂术甘汤颗粒完成药品注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2509996117","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509996117?lang=zh_cn&edition=full","pubTime":"2025-02-07 16:24","pubTimestamp":1738916647,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海凯宝(300039.SZ)公告，公司近日收到国家药品监督管理局签发的苓桂术甘汤颗粒《药品注册证书》。公告显示，苓桂术甘汤颗粒的功能主治为：温阳化饮，健脾利湿。用于中阳不足之痰饮。症见胸胁支满，目眩心悸，短气而咳，舌苔白滑，脉弦滑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1247083.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"上海凯宝(300039.SZ)：苓桂术甘汤颗粒完成药品注册","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300039","BK0188","BK0028","BK0239"],"gpt_icon":0},{"id":"2504406617","title":"【上海凯宝：获得药品注册证书】上海凯宝公告，公司近日收到国家药品监督管理局签发的一贯煎颗粒《药品注册证书》。一贯煎颗粒为处方药，规格为每袋相当于饮片7.77g，每袋装8g，每盒装20袋，药品有效期为24个月。该药品的功能主治为滋阴疏肝，用于肝阴不足，血燥气郁证，症见胸脘胁痛，吞酸吐苦，咽干口燥，舌红少津，脉细弦。亦治疝气瘕聚。获得药品注册证书有助于提升公司产品的市场竞争力，促进古代经典名方新药转化及其在现代临床中的广泛应用。","url":"https://stock-news.laohu8.com/highlight/detail?id=2504406617","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504406617?lang=zh_cn&edition=full","pubTime":"2025-01-20 19:34","pubTimestamp":1737372851,"startTime":"0","endTime":"0","summary":"上海凯宝公告，公司近日收到国家药品监督管理局签发的一贯煎颗粒《药品注册证书》。一贯煎颗粒为处方药，规格为每袋相当于饮片7.77g，每袋装8g，每盒装20袋，药品有效期为24个月。该药品的功能主治为滋阴疏肝，用于肝阴不足，血燥气郁证，症见胸脘胁痛，吞酸吐苦，咽干口燥，舌红少津，脉细弦。亦治疝气瘕聚。获得药品注册证书有助于提升公司产品的市场竞争力，促进古代经典名方新药转化及其在现代临床中的广泛应用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/20193447619334.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0188","BK0028","300039","BK0239"],"gpt_icon":0},{"id":"2504406734","title":"上海凯宝最新公告：获得一贯煎颗粒药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2504406734","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504406734?lang=zh_cn&edition=full","pubTime":"2025-01-20 19:30","pubTimestamp":1737372627,"startTime":"0","endTime":"0","summary":"上海凯宝公告，近日收到国家药品监督管理局签发的一贯煎颗粒《药品注册证书》。该药品为中药3.1类，规格为每袋相当于饮片7.77g，包装规格为每袋装8g，每盒装20袋，药品有效期为24个月，属于处方药。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025012000028974.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300039","BK0028","BK0239","BK0188"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770240090612,"stockEarnings":[{"period":"1week","weight":-0.0158},{"period":"1month","weight":0.023},{"period":"3month","weight":-0.0173},{"period":"6month","weight":-0.0573},{"period":"1year","weight":0.05},{"period":"ytd","weight":0.0348}],"compareEarnings":[{"period":"1week","weight":-0.0118},{"period":"1month","weight":0.0196},{"period":"3month","weight":0.0236},{"period":"6month","weight":0.1285},{"period":"1year","weight":0.262},{"period":"ytd","weight":0.0336}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海凯宝药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"49334人(较上一季度减少6.04%)","perCapita":"18586股","listingDate":"2010-01-08","address":"上海市奉贤区工业综合开发区程普路88号","registeredCapital":"104600万元","survey":"　　上海凯宝药业股份有限公司的主营业务是现代中药研发、生产、销售。公司的主要产品是痰热清注射液。报告期内，公司荣获“中国医药市场药企排行榜（中药）2024中国医药市场药企排行榜（中药）TOP100”“2025中国中药研发实力前50强”“奉贤区2024年度财富百强企业”“2024年度上海市工业综合开发区年度影响力传播奖”“奉贤区劳模工匠育人实践基地”等荣誉称号。","listedPrice":38},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海凯宝(300039)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海凯宝(300039)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海凯宝,300039,上海凯宝股票,上海凯宝股票老虎,上海凯宝股票老虎国际,上海凯宝行情,上海凯宝股票行情,上海凯宝股价,上海凯宝股市,上海凯宝股票价格,上海凯宝股票交易,上海凯宝股票购买,上海凯宝股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海凯宝(300039)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海凯宝(300039)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}